

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation								
1. Given Name (First Name) Quentin	2. Surnai Anstee	me (Last Nam	ne)		3. Date 12-March-2020				
. Are you the corresponding author?									
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study									
6. Manuscript Identifying Number (if you know it)									
Section 2. The Work Under Co	nsidera	tion for Pu	ıblication						
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest? Yes V									
Section 3. Relevant financial a	ctivitie	s outside t	he submitted	work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest?  Ves  No									
If yes, please fill out the appropriate info	rmation b	elow.							
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Acuitas Medical				<b>✓</b>	Consultancy on behalf of Newcastle University				
Allergan/Tobira	<b>✓</b>	<b>✓</b>		<b>✓</b>	Consultancy on behalf of Newcastle University & Grant funding				
E3Bio				<b>✓</b>	Consultancy on behalf of Newcastle University				
Eli Lilly & Company Ltd				<b>✓</b>	Consultancy on behalf of Newcastle University				
Galmed				<b>✓</b>	Consultancy on behalf of Newcastle University				



	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
nfit SA	<b>✓</b>	<b>✓</b>		<b>✓</b>	Consultancy on behalf of Newcastle University
ead		<b>✓</b>		<b>✓</b>	Consultancy on behalf of Newcastle University & Speaker
unthal				<b>✓</b>	Consultancy on behalf of Newcastle University
perial Innovations				<b>✓</b>	Consultancy on behalf of Newcastle University
ercept Pharma Europe Ltd	<b>✓</b>			<b>✓</b>	Consultancy on behalf of Newcastle University & Grant funding via the EU IMI2 scheme
entiva				<b>✓</b>	Consultancy on behalf of Newcastle University
nssen				<b>✓</b>	Consultancy on behalf of Newcastle University
nes		<b>✓</b>			Speaker
dlmmune				<b>✓</b>	Consultancy on behalf of Newcastle University
wGene				<b>✓</b>	Consultancy on behalf of Newcastle University
zer Ltd	<b>✓</b>			<b>√</b>	Consultancy on behalf of Newcastle University & Grant funding via the EU IMI2 scheme
otor Pharma				<b>✓</b>	Consultancy on behalf of Newcastle University
vartis Pharma AG	<b>✓</b>			<b>√</b>	Consultancy on behalf of Newcastle University & Grant funding via the EU IMI2 scheme
bvie	<b>✓</b>				
IS		<b>✓</b>		<b>✓</b>	Consultancy on behalf of Newcastle University & Speaker
K	<b>✓</b>				Research grant funding
MBio				<b>✓</b>	Consultancy on behalf of Newcastle University
drigal				<b>√</b>	Consultancy on behalf of Newcastle University
vier				<b>√</b>	Consultancy on behalf of Newcastle University
pR1				<b>✓</b>	Consultancy on behalf of Newcastle University
Bio				<b>✓</b>	Consultancy on behalf of Newcastle University



Altimmune			<b>✓</b>	Consultancy on behalf of Newcastle University
AstraZeneca	<b>✓</b>		<b>✓</b>	Consultancy on behalf of Newcastle University
Axcella			<b>✓</b>	Consultancy on behalf of Newcastle University
Blade			<b>✓</b>	Consultancy on behalf of Newcastle University
BNN Cardio			<b>✓</b>	Consultancy on behalf of Newcastle University
Celgene			<b>✓</b>	Consultancy on behalf of Newcastle University
Cirius			<b>✓</b>	Consultancy on behalf of Newcastle University
CymaBay			<b>✓</b>	Consultancy on behalf of Newcastle University
Genentech			<b>✓</b>	Consultancy on behalf of Newcastle University
HistoIndex			<b>✓</b>	Consultancy on behalf of Newcastle University
ndalo			<b>✓</b>	Consultancy on behalf of Newcastle University
QVIA			<b>✓</b>	Consultancy on behalf of Newcastle University
Metacrine			<b>✓</b>	Consultancy on behalf of Newcastle University
North Sea Therapeutics			<b>✓</b>	Consultancy on behalf of Newcastle University
Novo Nordisk			<b>✓</b>	Consultancy on behalf of Newcastle University
oxel			<b>✓</b>	Consultancy on behalf of Newcastle University
Terns Terns			<b>✓</b>	Consultancy on behalf of Newcastle University
Viking Therapeutics			<b>✓</b>	Consultancy on behalf of Newcastle University
Glympse Bio	<b>√</b>			



Section 5.	Relationships not covered above						
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?						
	Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6.	Disclosure Statement						

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Anstee reports other from Acuitas Medical, grants, personal fees and other from Allergan/Tobira, other from E3Bio, other from Eli Lilly & Company Ltd, other from Galmed, grants, personal fees and other from Genfit SA, personal fees and other from Gilead, other from Grunthal, other from Imperial Innovations, grants and other from Intercept Pharma Europe Ltd, other from Inventiva, other from Janssen, personal fees from Kenes, other from MedImmune, other from NewGene, grants and other from Pfizer Ltd, other from Raptor Pharma, grants and other from Novartis Pharma AG, grants from Abbvie, personal fees and other from BMS, grants from GSK, other from NGMBio, other from Madrigal, other from Servier, other from EcoR1, other from 89Bio, other from Altimmune, grants and other from AstraZeneca, other from Axcella, other from Blade, other from BNN Cardio, other from Celgene, other from Cirius, other from CymaBay, other from Genentech, other from Histolndex, other from Indalo, other from IQVIA, other from Metacrine, other from North Sea Therapeutics, other from Novo Nordisk, other from Poxel, other from Terns, other from Viking Therapeutics, grants from Glympse Bio, outside the submitted work;

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

van Thiel 1



Section 1. Identif	fying Information						
1. Given Name (First Name) Ingo	2. Surname (L van Thiel	st Name)	3. Date 18-June-2020				
4. Are you the correspondin	g author? Yes	No Corresponding Aut Bethany Franks	thor's Name				
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study							
6. Manuscript Identifying Number (if you know it)							
Section 2. The Wo	ork Under Consideration	for Publication					
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  Vo							
Section 3. Releva	nt financial activities ou	side the submitted work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo							
Section 4. Intelle	ctual Property Patents	& Copyrights					
Do you have any patents,	whether planned, pending o	rissued, broadly relevant to th	ne work?				

van Thiel 2



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

van Thiel 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	aation							
Given Name (First Name)  MANUEL	Surname (Last Name)     ROMERO-GÓMEZ		3. Date 24-June-2020					
4. Are you the corresponding author?	Yes ✓ No	Corresponding Auth	nor's Name					
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study								
6. Manuscript Identifying Number (if you kr 20-20283	now it)							
		_						
Section 2. The Work Under Co	onsideration for Publi	cation						
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da			.) for				
Section 3. Relevant financial	activities outside the	submitted work.						
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	ibed in the instructions. Uport relationships that we lest?	se one line for each e	entity; add as many lines as you need					
Name of Entity	Grant	n-Financial Support?	Comments					
INTERCEPT	<b>/</b>							
GILEAD-SCIENCES	<b>✓</b>							
SHIONOGI			Fees for consulting					
ALFA-WASSERMAN			Fees for Lectures					
PROSCIENTO			Fees for consulting					
KALEIDO			Fees for consulting					
NOVONORDISK	✓		Fees for Lectures					
MSD			Fees for consulting					



Name of Publica	Grant? Person	al Non-Financial	7				
Name of Entity	Fees?	Support?	Other Com	ments			
BMS			Fees fo	r consulting			
ALLERGAN			Fees fo	r consulting			
BOEHRINGER-INGELHEIM			Fees fo	rconsulting			
Section 4. Intellectual Propert	y Patents & C	opyrights					
Do you have any patents, whether plann			2،ابروری و والم و م مور	Voc. (A)			
Do you have any patents, whether plann	ea, pending or iss	ued, broadly releva	int to the work:	Yes ✓ No			
Cartion 5							
Section 5. Relationships not c	overed above						
Are there other relationships or activities potentially influencing, what you wrote i			influenced, or th	at give the appearance of			
potentially influencing, what you wrote i	n the submitted v	vork!					
Yes, the following relationships/cond	litions/circumstan	ces are present (ex	plain below):				
✓ No other relationships/conditions/cir	cumstances that p	oresent a potential	conflict of intere	st			
A + +   - +	بالمحالين والموسي	L +	J :£	معامله والمناه والمناه والمراط والمراط			
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					ents.		
					ents.		
On occasion, journals may ask authors to	disclose further ii				ents.		
On occasion, journals may ask authors to Section 6. Disclosure Stateme	o disclose further in	nformation about r	eported relations	ships.	ents.		
On occasion, journals may ask authors to  Section 6. Disclosure Stateme  Based on the above disclosures, this form	o disclose further in	nformation about r	eported relations	ships.	ents.		
On occasion, journals may ask authors to Section 6. Disclosure Stateme	o disclose further in	nformation about r	eported relations	ships.	ents.		
On occasion, journals may ask authors to  Section 6. Disclosure Stateme  Based on the above disclosures, this form	o disclose further in	nformation about r	eported relations	ships.	ents.		
On occasion, journals may ask authors to Section 6.  Disclosure Stateme  Based on the above disclosures, this form below.  Dr. ROMERO-GÓMEZ reports grants from	nt n will automaticall	nformation about r y generate a disclo ts from GILEAD-SCI	sure statement, v	which will appear in the box			
On occasion, journals may ask authors to Section 6.  Disclosure Stateme  Based on the above disclosures, this form below.	nt  n will automaticall  n INTERCEPT, gran fees from PROCIEN ), personal fees fro	nformation about r y generate a disclo ts from GILEAD-SCI ITO, personal fees f	sure statement, v	which will appear in the box fees from SHIONOGI, persor			



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Franks 1



Section 1.	Identifying Inform	ation					
1. Given Name (Fir Bethany	st Name)	2. Surnamo	e (Last Nam	e)		3. Date 16-June-2020	
4. Are you the corr	4. Are you the corresponding author?   ✓ Yes   No						
5. Manuscript Title The Cost of Non-	e Alcoholic Steatohepati	is (NASH) ii	n Europe a	nd USA: the G	AIN Study		_
6. Manuscript Ider JHEPR-D-20-0003	ntifying Number (if you kn 32	ow it)					
Section 2.	The Work Under Co	nsiderati	on for Pu	blication			
any aspect of the si statistical analysis, Are there any rele If yes, please fill o	ubmitted work (including etc.)? evant conflicts of intere	but not limit st? Ye rmation be	ed to grants  S  N  Iow. If you	s, data monitori o	ng board, study	commercial, private foundation, etc.) f design, manuscript preparation, oress the "ADD" button to add a ro	
Name of Institut	ion/Company	Grant?	Personal Fees?	Non-Financia Support <mark>?</mark>	Other? C	omments	
Novo Nordisk		<b>✓</b>					
Gilead Sciences, Inc		✓					
Carlana							
Section 3.	Relevant financial	ctivities (	outside tl	ne submitte	d work.		
of compensation clicking the "Add Are there any rele	) with entities as descril +" box. You should rep evant conflicts of intere	oed in the in ort relation st? Ye	nstructions iships that es 🕡 N	s. Use one line were <b>present</b> o	for each entity	relationships (regardless of amoun y; add as many lines as you need by 5 months prior to publication.	
Section 4.	Intellectual Proper	y Paten	nts & Copy	yrights			
Do you have any	patents, whether planr	ed, pendin	g or issuec	l, broadly relev	ant to the wo	rk? ☐ Yes 📝 No	

Franks 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Miss. Franks repo	orts grants from Novo Nordisk, grants from Gilead Sciences, Inc, during the conduct of the study; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Franks 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

#### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# **Intellectual Property.**

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### Relationships not covered above. 5.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



	_						
Section 1.	Identifying Infor	mation					
1. Given Name (I Vanessa	First Name)	2. Surname (Last N Hebditch	lame)		3. Date 18-June-2020		
4. Are you the co	4. Are you the corresponding author?  ✓ Yes						
5. Manuscript Tit The Cost of No	tle n-Alcoholic Steatohepa	ntitis (NASH) in Europ	pe and USA: the GA	AIN Study			
6. Manuscript Id	entifying Number (if you	know it)					
Section 2.	The Work Under	Consideration for	Publication				
any aspect of the statistical analysis Are there any re If yes, please fill	submitted work (includir s, etc.)? elevant conflicts of inte	rest?  Yes formation below. If	rants, data monitorin	ng board, sti	ent, commercial, private foundation, etc.) founds to the udy design, manuscript preparation, type type the "ADD" button to add a row		
	ution/Company	Grant? Person		Other?	Comments		
HCD Economics		<b>✓</b>					
Section 3.	Relevant financia	l activities outsid	e the submitted	l work.			
of compensation	on) with entities as desc	ribed in the instruct	ions. Use one line f	for each er	cial relationships (regardless of amount atity; add as many lines as you need by a <b>36 months prior to publication</b> .		
•	elevant conflicts of inte I out the appropriate in		No				
ii yes, pieuse iiii	rout the appropriate in	Torrida de la companya de la company					
Name of Entity		Grant? Person	, ,	Other?	Comments		
Intercept Pharma Lt	td				Educational grant towards British Liver Trust's core patient services. The		
		<b>✓</b>			funder has no editorial involvement in any materials developed as a result of this grant.		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Novartis Pharma UK Ltd	<b>√</b>				Educational grant towards British Liver Trust's core patient services. The funder has no editorial involvement in any materials developed as a result of this grant.		
Continue							
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights				
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes V No		
Section 5. Relationships not c	overed	above					
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of		
Yes, the following relationships/cond	litions/cir	cumstance	es are present (exp	olain belo	w):		
No other relationships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict o	finterest		
At the time of manuscript acceptance, jo On occasion, journals may ask authors to							
Section 6. Disclosure Stateme	nt						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.							
Ms Hebditch reports grants from HCD E grants from Novartis Pharma UK Ltd, ou				study; gr	ants from Intercept Pharma Ltd,		



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Mabhala 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Mzwandile	2. Surname (Last Name) Mabhala	3. Date 24-June-2020
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Bethany Franks
5. Manuscript Title The Cost of Non-Alcoholic Steatohepat	titis (NASH) in Europe and	USA: the GAIN Study
6. Manuscript Identifying Number (if you k	now it)	
		_
Section 2. The Work Under C	onsideration for Public	cation
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ribed in the instructions. Us port relationships that we	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re <b>present during the 36 months prior to publication</b> .
Section 4. Intellectual Prope	rty Patents & Copyri	ghts
Do you have any patents, whether plan	nned, pending or issued, br	roadly relevant to the work? Yes V No

Mabhala 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	ving relationships/conditions/circumstances are present (explain below):
✓ No other relat	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements nals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Mabhala has	nothing to disclose.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Mabhala 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Morgan 1



Section 1.	Identifying Inform	ation		
1. Given Name (Fi George	rst Name)	2. Surname (Las Morgan	Name)	3. Date 16-June-2020
4. Are you the cor	responding author?	Yes ✓	No Corresponding A	
5. Manuscript Title The Cost of Non-		tis (NASH) in Eur	ope and USA: the GAIN St	udy
6. Manuscript Iden	ntifying Number (if you kn	ow it)		
Section 2.	The Work Under Co	onsideration f	r Publication	
any aspect of the s statistical analysis, Are there any rel If yes, please fill of	ubmitted work (including etc.)? evant conflicts of intere	but not limited to est? Yes ormation below.	grants, data monitoring boa	ernment, commercial, private foundation, etc.) for ard, study design, manuscript preparation, etc.) e entity press the "ADD" button to add a row.
Name of Institut	ion/Company	Grant? Perso	_   Oth	ner? Comments
Novo Nordisk		<b>✓</b>		
Gilead Sciences, Inc.		<b>√</b>		
	ı			
Section 3.	Relevant financial	activities outs	de the submitted wor	k.
of compensation clicking the "Adc Are there any rel	n) with entities as descri I +" box. You should rep evant conflicts of intere	bed in the instru port relationship est?	ctions. Use one line for ear that were <b>present durin</b> No	inancial relationships (regardless of amount ch entity; add as many lines as you need by og the 36 months prior to publication.
Section 4.	Intellectual Proper	ty Patents &	Copyrights	
Do you have any	patents, whether plani	ned, pending or	ssued, broadly relevant to	o the work? Yes V No

Morgan 2



Continu F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Mr. Morgan repo	orts grants from Novo Nordisk and Gilead Sciences, Inc. to HCD Economics to sponsor the study presented of.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Morgan 3



#### Instruct ons

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# **Intellectual Property.**

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to

your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other





affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to

your patent



Section 1. Identifying I		
Identifying I	nformation	
1. Given Name (First Name) HARPAL	2. Surname (Last Name) DHILLON	3. Date 16-June-2020
4. Are you the corresponding author?	Yes No	Corresponding Author's Name Bethany Franks
5. Manuscript Title		
The Cost of Non-Alcoholic Steat	ohepatitis (NASH) in Europe	e and USA: the GAIN Study
6. Manuscript Identifying Number (i	f you know it)	
Section 2. The Work Und	ler Consideration for Pu	ublication
etc.) for any aspect of the submitted preparation statistical analysis etc.) Are there any relevant conflicts of	work (including but not limite of interest? ves No	
If yes, please fill out the appropr	iate information below. If yo	ou have more than one entity press the "ADD" button to
Name of	Grant? Personal No	on-Financial Other?
add a row. Excess rows can be re	emoved by pressing the "X"	button.  UNRESTRICTED GRANT  X
NOVO NORDISK		UNRESTRICTED GRANT X
		ADI
Section 3. Relevant finar	ncial activities outside th	ne submitted work.
amount of compensation) with e	entities as described in the indicate the indicate the second of the sec	ate whether you have financial relationships (regardless of nstructions. Use one line for each entity; add as many lines rt relationships that were <b>present during the 36 months</b>
		ADD



Section 4.

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes 

No



# Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. Section 6. Disclosure Statement Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. Generate Disclosure Statement Dr. HARPAL DHILLON reports grants from GILEAD, grants from NOVO NORDISK, during the conduct of the study;

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

RUIZ CASAS 1



Section 1.	Identifying Inform	ation				
1. Given Name (Fi LEONARDO	rst Name)	2. Surnar RUIZ CAS	ne (Last Name) SAS			3. Date 16-June-2020
4. Are you the cor	responding author?	Yes	✓ No	Correspond Bethany F	_	or's Name
5. Manuscript Title The Cost of Non-	e -Alcoholic Steatohepati	tis (NASH)	in Europe and	USA: the GAI	IN Study	
6. Manuscript Idei	ntifying Number (if you kn	ow it)				
	ı					
Section 2.	The Work Under Co	onsiderat	tion for Publ	ication		
any aspect of the s statistical analysis, Are there any rel If yes, please fill o	ubmitted work (including etc.)? evant conflicts of intere	but not limest?	nited to grants, do Yes No elow. If you ha	ata monitoring	g board, s	nent, commercial, private foundation, etc.) for tudy design, manuscript preparation, tity press the "ADD" button to add a row.
Name of Institut	, .	Grant?	Personal No	on-Financial Support	Other	Comments
GILEAD		<b>✓</b>				UNRESTRICTED GRANT
NOVO NORDISK		✓				UNRESTRICTED GRANT
	ı					
Section 3.	Relevant financial	activities	outside the	submitted	work.	
of compensation clicking the "Adc Are there any rel	n) with entities as descri I +" box. You should rep evant conflicts of intere	bed in the port relation est?	instructions. Unships that we	Jse one line fo ere <b>present d</b>	or each e	cial relationships (regardless of amount entity; add as many lines as you need by ne <b>36 months prior to publication</b> .
Section 4.	Intellectual Proper	ty Pate	nts & Copyri	ights		
Do you have any	patents, whether plani	ned, pendi	ng or issued, b	roadly releva	ant to the	e work? ☐ Yes 🗸 No

RUIZ CASAS 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. RUIZ CASAS r	eports grants from GILEAD, grants from NOVO NORDISK, during the conduct of the study;.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

RUIZ CASAS 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Schattenberg 1



Section 1. Identifying Inform	ation				
1. Given Name (First Name) Jörn	2. Surname (Last Name Schattenberg	)		Date -June-2020	
4. Are you the corresponding author?	☐ Yes ✓ No	Correspondi Bethany Fra	ng Author's Name anks		
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatir	tis (NASH) in Europe an	nd USA: the GAIN	Study		
6. Manuscript Identifying Number (if you kn JHEPR-D-20-00032	ow it)				
Section 2. The Work Under Co	onsideration for Pub	olication			
Did i di di di di		.1 . 1			
Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intered in the state of the submitted work in the state of the state	but not limited to grants, est? Yes No ormation below. If you h	, data monitoring	board, study design	ı, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info	but not limited to grants, est? Yes No prmation below. If you h	, data monitoring of	board, study design	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing	est? Yes No primation below. If you had the "X" button.	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company	est? Yes No rmation below. If you h g the "X" button.  Grant? Personal N Fees?	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company  GILEAD	but not limited to grants, est? Yes No ormation below. If you h g the "X" button.  Grant? Personal Fees?	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company  GILEAD  NOVO NORDISK	but not limited to grants, est?	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company  GILEAD  NOVO NORDISK  Genfit	but not limited to grants, est?	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company  GILEAD  NOVO NORDISK  Genfit  Intercept Pharmaceuticals	but not limited to grants, est? Yes No ormation below. If you has the "X" button.  Grant? Personal Fees?  V V V	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company  GILEAD  NOVO NORDISK  Genfit  Intercept Pharmaceuticals	but not limited to grants, est? Yes No ormation below. If you had the "X" button.  Grant? Personal Fees?  V V  V	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info Excess rows can be removed by pressing Name of Institution/Company  GILEAD  NOVO NORDISK  Genfit Intercept Pharmaceuticals IQVIA  Madrigal	but not limited to grants, est?	data monitoring of the control of th	board, study design one entity press th	n, manuscript prepa	ration,

Schattenberg 2



Section 3. Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V
Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Schattenberg reports grants and personal fees from GILEAD, personal fees from NOVO NORDISK, personal fees from Genfit, personal fees from Intercept Pharmaceuticals, personal fees from IQVIA, personal fees from Madrigal, personal fees from Roche, personal fees from Siemens Healthineers, from Pfizer during the conduct of the study.

Schattenberg 3



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Schattenberg 4



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Pedra 1



Section 1.	Identifying Inform	ation				
1. Given Name (Fi Gabriel	rst Name)	2. Surname (	Last Name)	3. Date 16-June-2020		
4. Are you the corresponding author?		Yes	✓ No	Corresponding Author's Name Bethany Franks		
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study						
6. Manuscript Iden	ntifying Number (if you kn	ow it)				
Section 2.	The Work Under Co	onsideratio	n for Publ	ation		
any aspect of the s statistical analysis, Are there any rel If yes, please fill of	ubmitted work (including etc.)? evant conflicts of intere	but not limited st? Yes rmation belo	d to grants, d  No  W. If you ha	a third party (government, commercia a monitoring board, study design, ma e more than one entity press the "	nuscript preparation,	
Name of Institut	, .	Grant? Pe	rsonal No	-Financial Other? Comments	;	
Novo Nordisk		<b>✓</b>				
Gilead Sciences, Inc.		<b>✓</b>				
	ı					
Section 3.	Relevant financial	activities ou	ıtside the	ubmitted work.		
of compensation clicking the "Adc Are there any rel	n) with entities as descri I +" box. You should rep evant conflicts of intere	bed in the ins port relationsh st? Yes	tructions. Unips that we	ether you have financial relationsh e one line for each entity; add as n e <b>present during the 36 months</b>	nany lines as you need by	
Section 4.	Intellectual Proper	ty Patent	s & Copyri	hts		
Do you have any	patents, whether plani	ned, pending	or issued, b	padly relevant to the work?	es 🗸 No	

Pedra 2



Section 5.				
Section 5.	Relationships not covered above			
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?			
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):			
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest			
	At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.			
Section 6.	Disclosure Statement			
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box			
Dr. Pedra reports	s grants from Novo Nordisk, grants from Gilead Sciences, Inc., during the conduct of the study; .			

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Pedra 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Jönsson 1



Section 1.	Identifying Inform	ation		
1. Given Name (Fir Bengt	rst Name)	2. Surname (Last Name) Jönsson		3. Date 25-June-2020
4. Are you the corr	responding author?	Yes ✓ No	Corresponding Author's Nar Bethany Franks	me
5. Manuscript Title The Cost of Non-		tis (NASH) in Europe and	USA: the GAIN Study	
6. Manuscript Ider	ntifying Number (if you kn	now it)		
			_	
Section 2.	The Work Under Co	onsideration for Public	cation	
any aspect of the si statistical analysis,	ubmitted work (including	but not limited to grants, da	a third party (government, coi ata monitoring board, study de	mmercial, private foundation, etc.) for sign, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	submitted work.	
of compensation clicking the "Add	) with entities as descri	bed in the instructions. Use port relationships that we	se one line for each entity; a	ationships (regardless of amount add as many lines as you need by nonths prior to publication.
Section 4.	Intellectual Proper	ty Patents & Copyri	ghts	
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work?	Yes 🗸 No

Jönsson 2



Section 5. Polotionships not solvered above			
Relationships not covered above			
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?			
Yes, the following relationships/conditions/circumstances are present (explain below):			
✓ No other relationships/conditions/circumstances that present a potential conflict of interest			
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.			
Section 6. Disclosure Statement			
Disclosure Statement			
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.			
Dr. Jönsson has nothing to disclose.			

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Jönsson 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Finnegan 1



Section 1.	Identifying Inform	ation					
Given Name (First Name)  Alan		2. Surname Finnegan	2. Surname (Last Name) Finnegan		3. Date 16-June-2020		
4. Are you the corresponding author?		Yes	<b>✓</b> No	-	Corresponding Author's Name Bethany Franks		
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study							
6. Manuscript Iden	ntifying Number (if you kn	ow it)					
Section 2.	The Work Under Co	onsiderati	on for Pub	lication			
any aspect of the s statistical analysis, Are there any rel If yes, please fill o	ubmitted work (including etc.)? evant conflicts of intereout the appropriate info	but not limit st? Ye rmation be	ted to grants, es No low. If you h	data monitorin	g board, s	nent, commercial, private foundation, etc.) for study design, manuscript preparation, tity press the "ADD" button to add a row.	
	be removed by pressing			on-Financial			
Name of Institut	ion/Company	Grant?	Personal N Fees	Support <mark>?</mark>	Other	Comments	
Gilead		<b>✓</b>				Unrestricted grant	
Novo Nordisk		✓				Unrestricted Grant	
Section 3.	Relevant financial	activities (	outside the	e submitted	work.		
of compensation clicking the "Adc Are there any rel	n) with entities as descri I +" box. You should rep evant conflicts of intere	bed in the i port relation st? Ye	nstructions. nships that w es 🕡 No	Use one line f vere <b>present c</b>	or each e	ncial relationships (regardless of amount entity; add as many lines as you need by ne 36 months prior to publication.	
Section 4.	Intellectual Proper	ty Pater	nts & Copy	rights			
Do you have any	patents, whether plani	ned, pendin	g or issued,	broadly releva	ant to the	e work? ☐ Yes 🗸 No	

Finnegan 2



Section 5. Polotionships not solvered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr Alan Finnegan reports grants from Gilead and grants from Novo Nordisk during the conduct of the study.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Finnegan 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

BUGIANESI 1



Section 1. Identifying Inform	nation				
identifying inform	iation				
1. Given Name (First Name) ELISABETTA	2. Surname (Last Name) BUGIANESI		3. Date 17-June-2020		
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Bethany Franks			
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study					
6. Manuscript Identifying Number (if you kr	now it)				
Section 2. The Work Under Co	onsideration for Publ	ication			
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	g but not limited to grants, dest?  Yes  No	lata monitoring board, s			
If yes, please fill out the appropriate info Excess rows can be removed by pressin		ive more than one ent	ity press the "ADD" button to add a row.		
Name of Institution/Company	Grant? Personal No	on-Financial Support?	Comments		
GILEAD			ADVISOR		
NTERCEPT			ADVISOR		
BMS			ADVISOR		
NOVO NORDISK			ADVISOR		
Section 3. Relevant financial	activities outside the	submitted work.			
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re Are there any relevant conflicts of intere	ibed in the instructions. Uport relations we	Jse one line for each e			
Are there any relevant connicts of intere	est: Tes 14 NO				

BUGIANESI 2



Section 4.	Intellectual Property Patents & Copyrights
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work? Yes V No
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	eports personal fees from GILEAD, personal fees from INTERCEPT, personal fees from BMS, personal fees RDISK, during the conduct of the study; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

BUGIANESI 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

O'Hara 1



Section 1.	Identifying Inform	ation					
Given Name (First Name)  Jamie		2. Surnam O'Hara	e (Last Name)		3. Date 17-June-2020		
4. Are you the corresponding author?		Yes	✓ No	-	Corresponding Author's Name Bethany Franks		
5. Manuscript Title The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study							
6. Manuscript Iden	ntifying Number (if you kn	ow it)					
Section 2.	The Work Under Co	nsiderati	ion for Pub	lication			
any aspect of the s statistical analysis, Are there any rel If yes, please fill o	stitution <b>at any time</b> recei ubmitted work (including etc.)? evant conflicts of intere	ve payment but not limiest? Yourmation be	or services fro ted to grants, o es No elow. If you ha	m a third party data monitorin	g board, s	nent, commercial, private foundation, etc.) for study design, manuscript preparation, tity press the "ADD" button to add a row.	
Name of Institut	ion/Company	Grant?	_	on-Financial Support <mark>?</mark>	Other	Comments	
Gilead Inc		<b>✓</b>				Unrestricted grant	
Novo Nordisk		✓				Unrestricted grant	
Section 3.	Relevant financial	activities	outside the	submitted	work.		
of compensation clicking the "Adc Are there any rel	n) with entities as descri I +" box. You should rep evant conflicts of intere	bed in the i port relation est? Y	instructions. Inships that wes	Use one line f ere <b>present c</b>	or each e	ncial relationships (regardless of amount entity; add as many lines as you need by ne 36 months prior to publication.	
Section 4.	Intellectual Proper	ty Pater	nts & Copyr	ights			
Do you have any	patents, whether plani	ned, pendir	ng or issued, l	oroadly releva	ant to the	e work? ☐ Yes 🗸 No	

O'Hara 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Mr O'Hara report	s grants from Gilead Inc, grants from Novo Nordisk, during the conduct of the study; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

O'Hara 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Reic 1



Section 1. Identifying Info	rmation						
1. Given Name (First Name) Tatjana	2. Surname (Last Name) Reic		3. Date 17-June-2020				
4. Are you the corresponding author?	4. Are you the corresponding author? ✓ Yes No						
5. Manuscript Title The Cost of Non-Alcoholic Steatoher	patitis (NASH) in Europe an	d USA: the GAIN Study					
6. Manuscript Identifying Number (if you	ı know it)	·					
Section 2. The Work Under	· Consideration for Pub	olication					
any aspect of the submitted work (include statistical analysis, etc.)?  Are there any relevant conflicts of int	ling but not limited to grants,	data monitoring board, st	ent, commercial, private foundation, etc.) for udy design, manuscript preparation,				
Section 3. Relevant financi	al activities outside th	e submitted work.					
	scribed in the instructions. report relationships that verest?	Use one line for each er vere <b>present during the</b>	cial relationships (regardless of amount ntity; add as many lines as you need by a 36 months prior to publication.				
Name of Entity	Grant? Personal Fees?	Ion-Financial Other?	Comments				
Gilead	<b>✓</b>		UNRESTRICTED GRANT to ELPA				
NOVO NORDISK	<b>✓</b>		RESTRICTED GRANT to ELPA				
Boeringhem Ingelheim	<b>✓</b>		RESTRICTED GRANT to ELPA				
BMS	<b>✓</b>		RESTRICTED GRANT to ELPA				
Genfit/NASH educational program	<b>✓</b>		RESTRICTED GRANT to ELPA				
Intercept			RESTRICTED GRANT to ELPA				

Reic 2



Cartina	
Section 4.	Intellectual Property Patents & Copyrights
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work? Yes V No
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
•	grants from Gilead, grants from NOVO NORDISK, grants from Boeringhem Ingelheim, grants from BMS, ifit/NASH educational program, grants from Intercept, outside the submitted work;.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Reic 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Ratziu 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Vlad	2. Surname (Last Name) Ratziu	3. Date 16-June-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name
5. Manuscript Title The Cost of Non-Alcoholic Steatohepat	itis (NASH) in Europe and (	JSA: the GAIN Study
6. Manuscript Identifying Number (if you kr	now it)	
Section 2. The Work Under Co	onsideration for Public	cation
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No		
Section 3. Relevant financial	activities outside the s	submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V		
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No

Ratziu 2



Section 5. Polationships not sovered shows		
Relationships not covered above		
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?		
Yes, the following relationships/conditions/circumstances are present (explain below):		
✓ No other relationships/conditions/circumstances that present a potential conflict of interest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement on occasion, journals may ask authors to disclose further information about reported relationships.		
Section 6. Disclosure Statement		
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.		
Dr. Ratziu has nothing to disclose.		

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Ratziu 3